Semaphorin 4D (Sema4D) has been proven to be one of the hypoxia effectors regulated by hypoxia inducible factor (HIF-1) in multiple cells, and play a role in angiogenesis like VEGF. However, the regulatory sequence characteristics of the Sema4D are not clarified. The possible hypoxia response element (HRE) sequences in 5' non-coding Region before ATG start codon of Sema4D were screened, followed by point mutagenesis and luciferase assay analysis. Sequencing and alignment of this region in 11 cancer cell lines and 4 normal cell lines were also performed, followed by cloning, mutation and luciferase assay analysis. The results showed that there were four possible HREs (HRE1-4) sequences in 1275bp range before ATG start codon. Among HRE1-4, HRE2 and HRE4 were functional HIF-1α binding sites. In addition, these two binding sites play different roles in the regulation of Sema4D expression in HUVEC and Caco-2 cells. There were three nucleotide variants (T471C/A600G/C862T) frequently detected in cancer cell lines. The site variation rates of T471C/A600G/C862T were 72.7%, 18.2%, and 72.7% in cancer cells respectively. Luciferase assays showed that T471C and C862T could significantly increase the expression efficiency of downstream target genes. Furthermore, secondary structure prediction showed that mutations at T471C and C862T apparently lead to change of the gene structure. Our study describes the sequence characteristics of 5' non-coding region of Sema4D, enhances our understanding of the regulatory mechanism of Sema4D and benefits the development of a possible anti-angiogenesis therapeutic strategy for malignancies.
Introduction
Semaphorin 4D (Sema4D) belongs to the semaphorin family, which binds to receptors such as Pleixn-B1 (transmembrane structure receptor), CD72 (cluster of differentiation antigen 72, mainly expresses on lymphocyte cells), then activates downstream signaling molecules. A previous study showed that Sema4D could be a pro-vascular element in cancer (1) (2) (3) . In PAE cells, soluble Sema4D promoted cell migration and developed a "tubulogenic" phenotype (4) . As a proangiogenic response effecter, the interaction of Sema4D with plexin-B1 is dependent on the COOH-terminal PDZ-binding motif of plexin-B1, which binds two guanine nucleotide exchange factors (GEFs) for Rho and is mediated by the activation of Rho-initiated (Ras homolog gene family) pathways (4) (5) (6) (7) (8) . Sema4D is regulated by HIF-1 and plays a role in tumor-associated macrophage-induced metastatic behavior and is clinically significant in colon cancer
Ivyspring
International Publisher (9) . Furthermore, studies have shown HIF-mediated Sema4D induction in the generation of the pro-angiogenic phenotype in oral squamous cell carcinoma (OSCC) and have determined its biological significance for tumor growth and vascularity (10) .
Hypoxia is the most common characteristic in the microenvironment of solid tumors because tumor progression and metastasis depend on the ability of cancer cells to initiate angiogenesis and ensure the delivery of oxygen and nutrients (11, 12) . HIF-1 works in multiple cell-autonomous and non-cellautonomous processes such as metabolism, angiogenesis, matrix invasion, and cancer metastasis by binding with target genes (13) (14) (15) . HIF-1 consists of two parts, HIF-1α and HIF-1β. HIF-1α contacts DNA directly and binds to DNA much more strongly than HIF-1β (16) . In hypoxia, the HIF-1 transcriptional complex drives the induction or repression of a myriad of genes through binding to hypoxia response elements (HREs, 5'-RCGTG-3') within the untranslated region of target genes (11) . In hypoxic tissues, hypoxia inducible factor HIF-1α is accumulated and stimulates the transcription of genes that have HREs in their promoters, including Sema4D (17) . Previous research showed that Sema4D is induced by hypoxia in a HIF-1-dependent manner and influences endothelial cell migration and tumor vascularity; however, the specific regulatory mechanism was not yet classified (10, 18) .Sema4D has been proven to be a hypoxia effector and regulated by HIF-1 in cancer cells (10) . However, the actual binding sequence of the HIF-1 complex is yet to be elucidated. The regulatory sequence characteristics of the Sema4D 5' non-coding region remain unclear in normal and cancer cells. It has been predicted that the Sema4D promoter region is likely regulated by a variety of factors. The sequence characteristics of the Semaphorin 4D 5' non-coding region require further elucidation. In this study, we attempted to determine the HRE binding sites, the important variants sequences before ATG start codon of SEMA 4D and possible biological effects.
Materials and Methods

Cell culture
Cancer cells, including A549 (lung cancer cell), Caco-2 (colorectal cancer cell), CNE (nasopharyngeal carcinoma cell), RD (rhabdomyoma cell), Tca8113 (tongue cancer cell), SK-OV-3 (ovarian cancer cell), Jurkat (acute T cell leukemia cell), HepG-2 (liver cancer cell), SK-N-SH (neuroblastoma cell), HL-60 (anterior myeloid cells), U937 (histiocytic lymphoma cell), and normal cells, including BEAS-2B (bronchial epithelial cell), HUVEC (human umbilical vein 
Immunoblot analysis
Cells were lysed in RIPA buffer (R0010, Solarbio, Beijing, China) with protease inhibitors (0.5 mM phenylmethylsulfonyl fluoride, Sigma, USA) for 20 min at 4 °C and collected in 1.5 mL Eppendorf tubes, followed by centrifugation (14000 g, 10 min). The precipitate was discarded and protein concentrations were measured using the BCA Protein Assay Kit (P0010S, Beyotime biotechnology, Beijing, China). Forty micrograms of protein from each sample were subjected to SDS-PAGE followed by transfer onto a PVDF membrane (IPVH00010, Immobilon P, Millipore, Bedford, MA). The membrane was then probed for HIF-1α, Sema4D, using β-actin as a loading control. The primary antibodies used were as follows: rabbit anti-Sema4D (610670, BD Biosciences, 150 kDa); mouse anti-HIF-1α (D43B5, Cell Signaling Technology, 120 kDa), rabbit anti-β-actin (P30002, Abmart, 42 kDa). The secondary antibodies used were as follows: goat anti-mouse IgG (H+L) peroxidase labeled (074-1806, KPL, MD, USA), goat anti-rabbit IgG (H+L) peroxidase labeled (074-1506, KPL, MD, USA). Antigen-antibody binding was detected using Luminata Crescendo Western HRP substrate (WBLUR0100, Millipore, MA, USA).
Hypoxia assays
Hypoxic environments were created by chemical methods. Caco-2 cells and HUVECs were cultured in DMEM with 0.2 mM CoCl 2 at 37 °C and 5% CO 2 . For detecting whether cells become "hypoxic", HIF-1α was detected by western blot since HIF-1α would accumulate in cells in hypoxic environment.
Chromatin Immunoprecipitation (ChIP) 1 x 10 6 cells on a 10 cm dish as appropriate were harvested after being incubated under hypoxia condition 12h. Then CHIP assay was performed with CHIP kit (17- 
Nucleotide secondary structure prediction
The Sema4D 5' non-coding region sequence was obtained from NCBI (LOC105584284). HIF-1α-HREs within the Sema4D 5'non-coding region were scanned on the Promoter 2.0 Prediction Server of the JASPAR database. The JASPAR matrix model is ARNT-HIF1A (MA0259.1), an Arnt (10009) class of basic helix-loop-helix factors in the PAS domain factor family, and the relative profile score threshold was set at 85% (Table 1) . DNA secondary structure analysis was performed in RNA structure 5.3.
Cloning of the regulatory sequence within Sema4D 5' non-coding region and luciferase assays
Genomic DNA of the 16 cell lines included in the study was isolated by the Wizard Genomic DNA Purification Kit (A1120, Promega, USA). The regulatory sequence was cloned by PCR. Primers for amplifying the regulatory sequence were designed by Premier Primer 5.0 (sense: 5'-TGAGGTTCTGTTTCG GCTGT-3', antisense: 5'-AATGCCATCGCTGTCCCA AA-3'). Plasmids (pRL-CMV vector, pGL3 luciferase reporter vector) for luciferase assays were purchased from Promega. The 5' untranslated region of Sema4D was cloned into the pGL3 luciferase reporter vector, while pRL-CMV acted as an internal reference. Detecting primers of pGL3 luciferase reporter vector are sense: 5'-CTAGCAAAATAGGCTGTCC-3', antisense:
5'-CTTTATGTTTTTGGCGTCTTCCA-3'. Both of these plasmids were transfected into Caco-2 and HUVEC lines. Cells were harvested in 40h after transfection, and luminescence was detected followed by Dual-Glo Luciferase assay system kit (E1910, promega, USA) introduction using Synergy 4 (BioTek). The parameters used were detection by luminescence detection method, endpoint read type, standard dynamic range, and the sensitivity was set to 200.
Statistical analysis
Fisher's Exact Test was used to determine the differences between different groups. P values were calculated to determine whether the two groups differed significantly from each other (* p<0.05; ** p<0.01).
Results
Accession Sequence ID
The regulatory sequences within Sema4D 5' non-coding region of all 15 cell lines included in the study were upload to GenBank, and the sequence IDs are shown below. A549, KX018325; Caco-2, KX018326; CNE, KX018327; RD, KX018328; 293T, KX018329; BEAS-2B, KX018330; HUVEC, KX018331; MRC-5, KX018332; Tca8113, KX789515; SK-OV-3, KX789516; Jurkat, KX789517; HepG-2, KX789518; SK-N-SH, KX789519; HL-60, KX789520; and U937, KX789522.
Sema4D's expression was correlated with HIF-1α
To further verified the correlation between HIF-1 and Sema4D in HUVECs or Caco-2 cells, both cells were cultured in a hypoxic incubator or in medium with 0.2 mM CoCl 2 . The expression levels of Sema4D and HIF-1α were detected by western blotting at different times (0', 30', 60', 120', 240', and 360'). Expression levels of HIF-1α in both Caco-2 cells and HUVECs were increased in both the hypoxic culture and CoCl 2 (0.2 mM) treatment. Meanwhile, the expression level of Sema4D increased and correlated with HIF-1 in both cells (Fig. 1) . To investigate HIF-1 binding region, a CHIP assay have been performed. Fragments about 200bp bands were observed in the immunoprecipitated fragments from HRE1/2 and HRE4 in either HUVECs or Caco2 cells exposed to hypoxic conditions. The HRE sequence of VEGF promoter was used as the positive control (Fig. 1) . Results show that HIF-1α could bind with HREs within Sema4D 5' non-coding region, and Sema4D is regulated by hypoxia in both HUVEC and Caco2 cells. Meanwhile, this regulation occurs at the level of transcription (Fig. 2) .
The promoter of Sema4D was predicted in the Promoter 2.0 Prediction Server. Then, the 1275 bp 5' non-coding region upstream of Sema4D was screened for candidate HIF-1α binding sites. After scanning the HIF-1α binding sites within the Sema4D 5' non-coding region in the JASPAR database, 4 promising HREs were obtained, which were corresponding to other 3 HRE sites showed in figure  3 : 537-CTGCGTGG-544 (HRE1), 552-TCACGTGC-559 (HRE2), 553-CACGTG-558 (HRE2), and 556-GTGCGTGT-563 (HRE3) ( Table 1, Table 2 , Figure 3) .
The Sema4D gene contains four HRE sequences that were cloned, and site-directed mutagenesis within the HRE core sequences was conducted by overlap PCR (Fig. 3) . Regulatory sequences containing Mutated HREs were cloned into luciferase reporter vectors. In HUVECs, the mutation of HRE4 results in an enormous reduction of luciferase compared to the normal group (positive control). However, in Caco-2 cells, the mutation of HRE2 caused a tremendous reduction of luciferase compared to the normal Sema4D 5' non-coding region sequence (Fig. 4) .
Distinct site mutations (T471C/A600G/C862T) within Sema4D 5' non-coding region in cancer cells.
The regulatory sequences within Sema4D 5' non-coding regions of 11 cancer cell lines, including for A549, Caco-2, CNE, RD, Tca-8113, SK-OV-3, Jurkat, HepG-2, HL-60, SK-N-SH and U937, and 4 normal cell lines, namely, 293T, BEAS-2B, HUVEC, MRC-5, were sequenced and aligned. There were three distinct mutation sites (T471C/A600G/C862T) were detected ( Table 3 ). The mutation rates of T471C/A600G/C862T were 72.7%, 18.2%, and 72.7% in cancer cells, respectively. In normal cells, these 3 mutation rates were not dectected. The secondary structure of the regulatory sequences containing these distinct mutation sites was predicted using RNA structure 5.3 (Function-fold DNA single strand). The point mutations T471C and C862T led to fewer DNA ring structures, while C862T increased the distance between 665T-720T. As a result, point mutations on T471C and C862T led to change of the gene structure (Fig. 5) . 
Mutate ratio 53.3% 0.015 13.3% 0.352 53.3% 0.015
The reference sequence (Rf sequence) AL590233.23 is human genomic DNA from clone RP13-93L13 on chromosome 9 (95588~96862) contains Semaphorin4D cds. There was significant difference among cell lines including 11 tumor cell lines and 4 normal cell lines on site mutations T471C and C862T within Sema4D 5' Non-coding Conserved Region (P=0.015).
The biological effects of T471C/A600A/C862C nucleotide variants within the Sema4D 5' non-coding region in cancer cells
To evaluate the biological effects of the previously mentioned mutations, the Sema4D regulatory sequences with combinations of the three typical mutation sites in cancer cells or normal cells were cloned into luciferase report vectors, including group1 (T471C/A600A/C862C), group2 (C471C/ A600A/C862T), group3 (T471C/A600A/C862T), group4 (T471T/A600G/C862C), and group5 (T471T/A600G/C862C, acted as a control). The results showed that simultaneous mutation of T471C and C862T caused obviously higher gene expression efficiency. The single point mutation of A600G did not cause a significant change in the expression efficiency of luciferase (Fig. 6) .
Discussion
Sema4D was up-regulated expression in many tumor tissues and play a critical endothelial chemoattractant role in adenocarcinomas of the prostate, colon, breast and squamous cell carcinomas of the head, neck or lung under hypoxia condition (2, 19) . In hypoxic tissues, hypoxia inducible factor HIF-1α is accumulated and stimulates the transcription of genes that have HREs in their promoters by binding HRE, for example VEGF (10, 17 ). Liao's and Zhou's research showed that Sema4D is induced by hypoxia in a HIF-1-dependent manner and influences endothelial cell migration and tumor vascularity; (10, 18) . However, the specific regulatory mechanism was not yet classified. non-coding region were detected in 7 cancer cell lines. The A600G mutation was detected in 2 cancer cell lines. These three mutations caused significant changes in the DNA secondary structure. The T471C point mutation caused fewer DNA rings between 390G-400G and loosened the tight structure between 450T-510C. The mutation at C862T exposed the retraction structure between 810C-830T, while C862T increased the distance between 665T-720T. In this study, our result demonstrated that HIF could regulate Sema4D transcript by binding HRE within Sema4D 5'uncoding region in both HUVECs and Caco-2 cells, then play a role in vascular induce under hypoxia condition which was similar to VEGF. In addition, the result showed that key HREs varied between tumor cells and normal cells, few study report similar result before and it interested us a lot. 3 distinct mutation sites were frequently detected within 5' un-coding region among 11 tumor cell strains (distinguish from 4 normal cells) and DNA secondary structure were predicted online. The result exhibit diversity in the predict DNA secondary structure among different Sema4D 5' uncoding region nucleotide variants. In addition, expression efficiency differs among cancer cells and normal cells with different nucleotide variants. It indicated that 5'uncoding region contained diversity nucleotide variants of cancer cells contributed to the difference of Sema4D expression. These data enhance our understanding of the regulatory mechanism of Sema4D expression. Considering Sema4D play a role in inducing vascular, the study will benefit the development of a possible therapeutic strategy for malignancies.
Four possible HREs in the Sema4D 5' non-coding region have been screened. The possible HRE sequences were then cloned in vectors, and site-directed mutation of the HRE core sequences was conducted by site-directed mutagenesis. The luciferase assay results showed that the key HIF-1α binding HRE sequence was HRE4 in HUVECs. While, the key HIF-1α binding HRE sequence was HRE2 in Caco-2 cells. Therefore, HIF-1 mainly combines with one of the four core HREs, and the key HRE is distinct in different cells.
Genomic DNA of 11 cancer cells (A549, Caco-2, CNE, RD, Tca8113, SK-OV-3, Jurkat, HepG-2, HL-60, U937, and SK-N-SH) and normal cells (293T, BEAS-2B, HUVEC, MRC-5,) were extracted, followed by sequencing of the Sema4D 5'non-coding region. Three distinctive point mutations (T471C/A600G/ C862T) were detected in the Sema4D 5' non-coding region in cancer cells. Except for SK-N-SH, HL-60, U937, the T471C mutation was detected in the other 8 cancer cell lines. Meanwhile, the C862T mutation was detected in 8 of the 11 cancer cell lines except for Caco-2 cell line. A600G is detected in several types of cancer cell lines, including CNE and Tca-8113, while this mutation was not detected in 4 of the normal cell lines analyzed. Meanwhile, T471C/C862T mutations were also rarely found in these normal cell lines. Our result reveals that the nucleotide variant T471C and C862T are quite important in cancer cells, which benefit from the expression of Sema4D. The T471C point mutation caused fewer DNA rings between 390G-400G and loosened the tight structure between 450T-510C. The mutation at C862T exposed the retraction structure between 810C-830T, and increased the distance between 665T-720T (Fig. 5) . These mutations which were close to the HIF-1α binding site may affect the HIF-1α or other factors combination due to the nucleotide secondary structure change.
There is a great need to enhance our understanding of the regulatory mechanism of the Sema4D 5' non-coding region. In this study, we showed that HRE4 and HRE2 play distinct regulatory roles in HIF-1 induced Sema4D unregulated expression in different cells. Additionally, the mutation sites of the Sema4D 5' non-coding region are distinctly different between normal and cancer cells, which affect the expression of Sema4D and lead to different biological effects.
